Author:
Kerut Christian K,Wagner Maxwell J,Daniel Charles P,Fisher Claire,Henderson Emmilee J,Burroughs Caroline R,Amarasinghe Sam,Willett Olga,Ahmadzadeh Shahab,Varrassi Giustino,Shekoohi Sahar,Kaye Alan D
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Development of therapeutic antibodies for the treatment of diseases;Lu RM;J Biomed Sci,2020
2. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis;Zhuang Y;Eur J Clin Pharmacol,2016
3. Guselkumab for the treatment of psoriasis;Machado Á;BioDrugs,2018
4. TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis. (2023). Accessed. March 19, 2023: https://www.jnj.com/tremfya-guselkumab-approved-by-u-s-food-and-drug-administration-as-the-first-selective-interleuki....
5. Clinically uninvolved but not healthy-The skin of patients with atopic dermatitis is primed for itch and inflammation;Moon S;J Eur Acad Dermatol Venereol,2023
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献